全文获取类型
收费全文 | 153篇 |
免费 | 11篇 |
国内免费 | 4篇 |
专业分类
儿科学 | 3篇 |
妇产科学 | 1篇 |
基础医学 | 20篇 |
口腔科学 | 11篇 |
临床医学 | 16篇 |
内科学 | 35篇 |
皮肤病学 | 8篇 |
神经病学 | 16篇 |
特种医学 | 7篇 |
外科学 | 12篇 |
预防医学 | 7篇 |
眼科学 | 2篇 |
药学 | 13篇 |
中国医学 | 1篇 |
肿瘤学 | 16篇 |
出版年
2023年 | 1篇 |
2022年 | 5篇 |
2021年 | 5篇 |
2020年 | 6篇 |
2019年 | 8篇 |
2018年 | 2篇 |
2017年 | 6篇 |
2016年 | 4篇 |
2015年 | 4篇 |
2014年 | 2篇 |
2013年 | 14篇 |
2012年 | 14篇 |
2011年 | 23篇 |
2010年 | 10篇 |
2009年 | 12篇 |
2008年 | 12篇 |
2007年 | 11篇 |
2006年 | 9篇 |
2005年 | 12篇 |
2004年 | 5篇 |
2003年 | 2篇 |
2002年 | 1篇 |
排序方式: 共有168条查询结果,搜索用时 0 毫秒
1.
Gavriatopoulou Maria Ntanasis-Stathopoulos Ioannis Korompoki Eleni Fotiou Despina Migkou Magdalini Tzanninis Ioannis-Georgios Psaltopoulou Theodora Kastritis Efstathios Terpos Evangelos Dimopoulos Meletios A. 《Clinical and experimental medicine》2021,21(2):167-179
Clinical and Experimental Medicine - The new type of coronavirus (COVID-19), SARS-CoV-2 originated from Wuhan, China and has led to a worldwide pandemic. COVID-19 is a novel emerging infectious... 相似文献
2.
3.
Parente Andrea de Vries Erik F. J. van Waarde Aren Ioannou Magdalini van Luijk Peter Langendijk Johannes A. Dierckx Rudi A. J. O. Doorduin Janine 《Molecular imaging and biology》2020,22(4):1012-1020
Molecular Imaging and Biology - Radiotherapy is a frequently applied treatment modality for brain tumors. Concomitant irradiation of normal brain tissue can induce various physiological responses.... 相似文献
4.
Papassotiropoulos A Lambert JC Wavrant-De Vrièze F Wollmer MA von der Kammer H Streffer JR Maddalena A Huynh KD Wolleb S Lutjohann D Schneider B Thal DR Grimaldi LM Tsolaki M Kapaki E Ravid R Konietzko U Hegi T Pasch T Jung H Braak H Amouyel P Rogaev EI Hardy J Hock C Nitsch RM 《Neuro-degenerative diseases》2005,2(5):233-241
Alzheimer's disease (AD) is the most common cause of dementia. It is characterized by beta-amyloid (A beta) plaques, neurofibrillary tangles and the degeneration of specifically vulnerable brain neurons. We observed high expression of the cholesterol 25-hydroxylase (CH25H) gene in specifically vulnerable brain regions of AD patients. CH25H maps to a region within 10q23 that has been previously linked to sporadic AD. Sequencing of the 5' region of CH25H revealed three common haplotypes, CH25Hchi2, CH25Hchi3 and CH25Hchi4; CSF levels of the cholesterol precursor lathosterol were higher in carriers of the CH25Hchi4 haplotype. In 1,282 patients with AD and 1,312 healthy control subjects from five independent populations, a common variation in the vicinity of CH25H was significantly associated with the risk for sporadic AD (p = 0.006). Quantitative neuropathology of brains from elderly non-demented subjects showed brain A beta deposits in carriers of CH25Hchi4 and CH25Hchi3 haplotypes, whereas no A beta deposits were present in CH25Hchi2 carriers. Together, these results are compatible with a role of CH25Hchi4 as a putative susceptibility factor for sporadic AD; they may explain part of the linkage of chromosome 10 markers with sporadic AD, and they suggest the possibility that CH25H polymorphisms are associated with different rates of brain A beta deposition. 相似文献
5.
Evangelos Terpos Anna Tasidou Efstathios Kastritis Evangelos Eleftherakis-Papaiakovou Maria Gavriatopoulou Magdalini Migkou Meletios-Athanassios Dimopoulos 《Clinical lymphoma & myeloma》2009,9(1):46-49
Angiogenesis represents an essential step of disease progression in several hematological malignancies. In Waldenström's macroglobulinemia (WM) the bone marrow microvessel density is increased in 30%–40% of patients but seems to have no impact on survival. Angiogenic cytokines, such as angiogenin, vascular endothelial growth factor, and basic fibroblast growth factor are increased in the serum of WM or IgM-MGUS patients, while the ratio of angiopoietin-1/angiopoietin-2 is reduced in WM but not in IgM—monoclonal gammopathy of undetermined significance (MGUS). Angiogenin and angiopoietin-1/angiopoietin-2 ratio correlates with disease activity and clinical features of WM. Macrophage and mast-cell chemoattractants, such as macrophage inflammatory protein-1 alpha are also elevated in the serum of patients with WM, while both macrophages and mast cells that are increased in the WM microenvironment have angiogenic properties and participate in the angiogenesis process in several malignancies. This review summarizes all data available by November 2008 (end of literature search) for the role of angiogenesis in the biology of WM and its correlation with clinical and laboratory features of the disease. 相似文献
6.
7.
Magdalini Moutaftsi Shahram Salek‐Ardakani Michael Croft Bjoern Peters John Sidney Howard Grey Alessandro Sette 《European journal of immunology》2009,39(3):717-722
The recent identification of a large array of different vaccinia virus‐derived CD8+ T‐cell epitopes offers a unique opportunity to systematically analyze the correlation between protective efficacy and variables such as kinetics of expression and function of viral proteins, binding affinity to MHC molecules, immunogenicity, and viral antigen processing/presentation. In the current study, 49 different H‐2b restricted epitopes were tested for their ability to protect peptide‐immunized C57Bl/6 mice from lethal i.n. challenge with vaccinia virus. The epitopes varied greatly in their ability to confer protection, ranging from complete protection with minimal disease to no protection at all. The function or kinetics of the viral antigen expression did not correlate with protective efficacy. However, binding affinity partially predicted protection efficacy and ultimately epitope immunogenicity and recognition of infected cells offered the best correlation. 相似文献
8.
Follicular dendritic cells control engulfment of apoptotic bodies by secreting Mfge8 总被引:1,自引:0,他引:1
Kranich J Krautler NJ Heinen E Polymenidou M Bridel C Schildknecht A Huber C Kosco-Vilbois MH Zinkernagel R Miele G Aguzzi A 《The Journal of experimental medicine》2008,205(6):1293-1302
The secreted phosphatidylserine-binding protein milk fat globule epidermal growth factor 8 (Mfge8) mediates engulfment of apoptotic germinal center B cells by tingible-body macrophages (TBMphis). Impairment of this process can contribute to autoimmunity. We show that Mfge8 is identical to the mouse follicular dendritic cell (FDC) marker FDC-M1. In bone-marrow chimeras between wild-type and Mfge8(-/-) mice, all splenic Mfge8 was derived from FDCs rather than TBMphis. However, Mfge8(-/-) TBMphis acquired and displayed Mfge8 only when embedded in Mfge8(+/+) stroma, or when situated in lymph nodes draining exogenous recombinant Mfge8. These findings indicate a licensing role for FDCs in TBMphi-mediated removal of excess B cells. Lymphotoxin-deficient mice lacked FDCs and splenic Mfge8, and suffer from autoimmunity similar to Mfge8(-/-) mice. Hence, FDCs facilitate TBMphi-mediated corpse removal, and their malfunction may be involved in autoimmunity. 相似文献
9.
Migkou M Kastritis E Roussou M Gkotzamanidou M Gavriatopoulou M Nikitas N Mparmparoussi D Matsouka C Gika D Terpos E Dimopoulos MA 《European journal of haematology》2011,87(4):323-329
Objectives: To assess the importance of the quality of response and of early relapse in unselected elderly patients with myeloma treated upfront with novel agents. Methods: We analyzed 135 unselected transplant‐ineligible patients older than 65 yr who were treated upfront with novel agent‐based regimens in a single center. Results: On intent to treat, 81% of patients achieved a response (28% sCR/CR, 23% VGPR, and 30% PR). Median progression‐free survival (PFS) for patients who achieved sCR/CR was 31 vs. 20 months for VGPR and 23 months for PR (P = 0.048). Median overall survival (OS) for patients with sCR/CR was 62 months, 53 months for VGPR and 38 months for patients with PR (P = 0.028). Early relapse (PFS < 12 months) was more common in patients with PR (39% vs. 21% for VGPR vs. 3% for sCR/CR). Patients who relapsed or progressed <12 months from initiation of treatment had a median OS of 15.4 months compared with 53 months (P < 0.001) for patients who had a PFS > 12 months despite the fact that after relapse or progression most patients were treated again with novel agents. In multivariate analysis, short PFS was the most significant adverse prognostic factor affecting OS, associated with a 7.25‐fold (P < 0.0001) increase in the risk of death. Conclusion: In newly diagnosed patients over 65 yr, treated upfront with novel agents achievement of CR and a PFS ≥12 months is associated with improved outcome. Patients who fail to respond or experience early relapse after primary therapy with novel agent‐based regimens should be encouraged to participate in clinical trials of novel agents and combinations. 相似文献
10.
Efstathios Kastritis Maria Roussou Maria Gavriatopoulou Magdalini Migkou Despina Kalapanida Constantinos Pamboucas Elisavet Kaldara Argyrios Ntalianis Erasmia Psimenou Savvas T. Toumanidis Anna Tasidou Evangelos Terpos Meletios A. Dimopoulos 《American journal of hematology》2015,90(4):E60-E65
Bortezomib and lenalidomide are increasingly used in patients with AL amyloidosis, but long term data on their use as primary therapy in AL amyloidosis are lacking while early mortality remains significant. Thus, we analyzed the long term outcomes of 85 consecutive unselected patients, which received primary therapy with bortezomib or lenalidomide and we prospectively evaluated a risk adapted strategy based on bortezomib/dexamethasone to reduce early mortality. Twenty‐six patients received full‐dose bortezomib/dexamethasone, 36 patients lenalidomide with oral cyclophosphamide and low‐dose dexamethasone and 23 patients received bortezomib/dexamethasone at a dose and schedule adjusted to the risk of early death. On intent to treat, 67% of patients achieved a hematologic response (24% hemCRs) and 34% an organ response; both were more frequent with bortezomib. An early death occurred in 20%: in 36% of those treated with full‐dose bortezomib/dexamethasone, in 22% of lenalidomide‐treated patients but only in 4.5% of patients treated with risk‐adapted bortezomib/dexamethasone. Activity of full vs. adjusted dose bortezomib/dexamethasone was similar; twice weekly vs. weekly administration of bortezomib also had similar activity. After a median follow up of 57 months, median survival is 47 months and is similar for patients treated with bortezomib vs. lenalidomide‐based regimens. However, risk adjusted‐bortezomib/dexamethasone was associated with improved 1‐year survival vs. full‐dose bortezomib/dexamethasone or lenalidomide‐based therapy (81% vs. 56% vs. 53%, respectively). In conclusion, risk‐adapted bortezomib/dexamethasone may reduce early mortality and preserve activity while long term follow up indicates that remissions obtained with lenalidomide or bortezomib may be durable, even without consolidation with alkylators.Am. J. Hematol. 90:E60–E65, 2015. © 2015 Wiley Periodicals, Inc. 相似文献